Marijuana stocks fell sharply after President Trump signed an executive order to reclassify marijuana as a less dangerous drug suitable for medical use, but stopped short of full legalization, making it a symbolic win for the industry without changing federal law or impacting markets significantly.
Tilray Brands' disappointing sales and net loss report have negatively impacted the entire marijuana stock market, with shares of Cronos Group, Canopy Growth, and Aurora Cannabis all suffering significant declines. Despite some growth in sales, Tilray's failure to achieve positive free cash flow has raised concerns about the prospects for the entire cannabis industry, leading analysts to predict that even larger companies like Aurora Cannabis, Canopy Growth, and Cronos may struggle to generate positive cash profits in the foreseeable future. As a result, investors are advised to exercise caution when considering investments in marijuana stocks, including Tilray Brands.
Marijuana stocks, including Tilray, Cronos Group, and Canopy Growth, surged as Vice President Kamala Harris expressed support for reducing federal regulation of marijuana in the U.S. and Germany passed a law to fully legalize the drug, set to take effect on April 1. This news, along with Canopy Growth's move to set up a Canopy USA holding company, drove stock prices up, with Tilray and Canopy Growth positioned to benefit the most from Germany's legalization.